Advertisement

Esophagus

pp 1–7 | Cite as

Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer

  • Koichi Okamoto
  • Itasu NinomiyaEmail author
  • Takahisa Yamaguchi
  • Shiro Terai
  • Shinichi Nakanuma
  • Jun Kinoshita
  • Isamu Makino
  • Keishi Nakamura
  • Tomoharu Miyashita
  • Hidehiro Tajima
  • Hiroyuki Takamura
  • Sachio Fushida
  • Tetsuo Ohta
Original Article
  • 83 Downloads

Abstract

Background

Chemotherapy, including preoperative chemotherapy, plays an important role in the treatment of esophageal cancer. However, although docetaxel, cisplatin, and fluorouracil (DCF) therapy has a powerful antitumor effect, the associated adverse events make it difficult to maintain the patient’s general condition. Oral mucositis is an important adverse effect of chemotherapy, and its severity, frequency, and impact on patient quality of life should not be underestimated. This study evaluated the role of oral cryotherapy for prophylaxis of oral mucositis caused by DCF therapy.

Methods

We retrospectively examined the incidence and severity of adverse events, including mucositis, in 72 patients with esophageal cancer treated with DCF. Fifty-eight patients received cryotherapy during docetaxel administration and 14 received no cryotherapy.

Results

The incidence of mucositis of all grades and grade 3 was significantly lower in the cryotherapy group compared with the no-cryotherapy group (24.1% vs. 71.4%, P < 0.001 and 0% vs. 28.6%, P = 0.001, respectively). The incidence of anorexia of all grades and grade 3 was also significantly lower in the cryotherapy group (22.4% vs. 57.1%, P = 0.037 and 0% vs. 28.6%, P = 0.010, respectively).

Conclusion

Adjunctive oral cryotherapy is effective for the prophylaxis and relief of oral mucositis and anorexia caused by chemotherapy.

Keywords

Cryotherapy Esophageal cancer Oral mucositis Chemotherapy Adverse event 

Notes

Acknowledgements

The authors gratefully thank the nurses and pharmacists involved in the clinical practice. We also thank Susan Furness, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Compliance with ethical standards

Ethical Statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or a substitute for it was obtained from all patients included in the study.

Conflict of interest

All authors declare no conflict of interest.

References

  1. 1.
    Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus. 2015;12:1–30.CrossRefGoogle Scholar
  2. 2.
    Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.CrossRefGoogle Scholar
  3. 3.
    Yokota T, Hatooka S, Ura T, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31(10):3535–41.Google Scholar
  4. 4.
    Nomura M, Oze I, Abe T, et al. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. Cancer Chemother Pharmacol. 2015;76(2):357–63.CrossRefGoogle Scholar
  5. 5.
    Tamura S, Imano M, Takiuchi H, et al. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res. 2012;32(4):1403–8.Google Scholar
  6. 6.
    Yamasaki M, Miyata H, Tanaka K, et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80(5–6):307–13.CrossRefGoogle Scholar
  7. 7.
    Hara H, Tahara M, Daiko H, et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104(11):1455–60.CrossRefGoogle Scholar
  8. 8.
    Osaka Y, Shinohara M, Hoshino S, et al. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res. 2011;31(2):633–8.Google Scholar
  9. 9.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991–7.CrossRefGoogle Scholar
  10. 10.
    Nishimura N, Nakano K, Ueda K, et al. Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas. Support Care Cancer. 2012;20(9):2053–9.CrossRefGoogle Scholar
  11. 11.
    Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109(5):820–31.CrossRefGoogle Scholar
  12. 12.
    Sonis S, Koplowsky A, Mitus J, et al. Relationship of chemotherapy-induced mucositis and myelosuppression in hamsters. Eur J Cancer B Oral Oncol. 1992;28B(1):43.CrossRefGoogle Scholar
  13. 13.
    Katranci N, Ovayolu N, Ovayolu O, et al. Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy—a randomized controlled trial. Eur J Oncol Nurs. 2012;16(4):339–44.CrossRefGoogle Scholar
  14. 14.
    Karagozoglu S, Filiz Ulusoy M. Chemotherapy: the effect of oral cryotherapy on the development of mucositis. J Clin Nurs. 2005;14(6):754–65.CrossRefGoogle Scholar
  15. 15.
    Worthington HV, Clarkson JE, Bryan G, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2011;5:4.  https://doi.org/10.1002/14651858.cd000978.Google Scholar
  16. 16.
    Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol. 1991;9(3):449–52.CrossRefGoogle Scholar
  17. 17.
    Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumors. 7th ed. Oxford Wiley-Blackwell 2010.Google Scholar
  18. 18.
    Flejou JF. WHO Classification of digestive tumors: the fourth edition. Ann Pathol. 2011;31(5 Suppl):S27–31.CrossRefGoogle Scholar
  19. 19.
    Berger MJ, Ettinger DS, Aston J, et al. NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017;15(7):883–93.CrossRefGoogle Scholar
  20. 20.
    Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119–33.CrossRefGoogle Scholar
  21. 21.
    Minami H, Kawada K, Sasaki Y, et al. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci. 2009;100(1):144–9.CrossRefGoogle Scholar
  22. 22.
    Liu YJ, Zhu GP, Guan XY. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol. 2012;48(6):554–9.CrossRefGoogle Scholar
  23. 23.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors European. Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.CrossRefGoogle Scholar
  24. 24.
    Isono KUY, Watanabe H. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: preface, general principles, part I. Esophagus. 2004;1:61–88.Google Scholar
  25. 25.
    Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis. 2006;12(3):229–41.CrossRefGoogle Scholar
  26. 26.
    Scotte F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23(19):4424–9.CrossRefGoogle Scholar
  27. 27.
    McCarthy AL, Shaban RZ, Gillespie K, et al. Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial. Support Care Cancer. 2014;22(5):1375–83.CrossRefGoogle Scholar
  28. 28.
    Shin H, Jo SJ, Kim DH, et al. Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis. Int J Cancer. 2015;136(5):E442–54.CrossRefGoogle Scholar
  29. 29.
    Riley P, Glenny AM, Worthington HV, et al. Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev. 2015;5:4.  https://doi.org/10.1002/14651858.cd011552.pub2(12).Google Scholar

Copyright information

© The Japan Esophageal Society and Springer 2019

Authors and Affiliations

  • Koichi Okamoto
    • 1
  • Itasu Ninomiya
    • 1
    Email author
  • Takahisa Yamaguchi
    • 1
  • Shiro Terai
    • 1
  • Shinichi Nakanuma
    • 1
  • Jun Kinoshita
    • 1
  • Isamu Makino
    • 1
  • Keishi Nakamura
    • 1
  • Tomoharu Miyashita
    • 1
  • Hidehiro Tajima
    • 1
  • Hiroyuki Takamura
    • 1
  • Sachio Fushida
    • 1
  • Tetsuo Ohta
    • 1
  1. 1.Department of Gastroenterological SurgeryKanazawa UniversityKanazawaJapan

Personalised recommendations